Metsera's (NASDAQ:MTSR - Get Free Report) lock-up period will end on Wednesday, July 30th. Metsera had issued 15,277,778 shares in its IPO on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on the company. Wells Fargo & Company initiated coverage on Metsera in a research report on Friday, June 20th. They issued an "overweight" rating and a $65.00 target price on the stock. Guggenheim boosted their price target on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research note on Tuesday, June 10th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Metsera presently has an average rating of "Buy" and a consensus target price of $55.00.
Check Out Our Latest Stock Analysis on MTSR
Metsera Trading Down 1.2%
Shares of MTSR opened at $39.45 on Wednesday. The company has a fifty day moving average of $30.49. Metsera has a fifty-two week low of $12.30 and a fifty-two week high of $47.40.
Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Strs Ohio acquired a new position in Metsera in the 1st quarter valued at approximately $76,000. New York State Common Retirement Fund bought a new position in shares of Metsera in the first quarter valued at approximately $131,000. Corebridge Financial Inc. acquired a new position in Metsera in the 1st quarter valued at $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Metsera in the 1st quarter worth $248,000. Finally, MetLife Investment Management LLC bought a new position in Metsera in the 1st quarter worth $254,000.
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
